Eli Lilly announced positive results from a Phase 2 clinical trial of an experimental combination treatment for obesity and Type 2 diabetes. The regimen pairs eloralintide, a drug targeting amylin, with a low dose of tirzepatide, which acts on GLP-1 and GIP gut hormones. The company believes that simultaneously engaging all three hormone pathways produces superior outcomes compared to single-agent approaches.
Patients receiving the highest dose combination achieved average weight loss of 23.3%, or approximately 54 pounds, compared to 14.8% weight loss, or 34.4 pounds, in those taking only tirzepatide at 15 milligrams. Eloralintide alone produced 12.3% average weight loss. The combination also demonstrated greater improvements in blood sugar control, reducing A1C levels by up to 2.9% on average versus 2.4% with high-dose tirzepatide alone.
However, the trial revealed tolerability concerns. Discontinuation rates due to adverse effects ranged from 10.8% to 27% depending on the combination dose, substantially higher than the 2.9% seen with tirzepatide monotherapy. Gastrointestinal side effects predominated and were generally mild to moderate, occurring primarily during dose escalation phases. Lilly executives noted that similar tolerability patterns emerged in earlier-stage studies of high-dose tirzepatide and indicated plans to adjust dosing schedules in upcoming Phase 3 trials.
Lilly intends to initiate Phase 3 studies by the end of 2026 and is developing a co-formulated single-injection version combining both drugs. The company plans to pursue dosing modifications expected to achieve a more favorable balance between efficacy and tolerability. Industry analysts have positioned the combination as a direct competitor to rival approaches targeting multiple hormone systems, particularly Novo’s CagriSema. Observers noted significant market potential, particularly among the millions of patients who have not achieved satisfactory results with existing obesity treatments or experienced intolerable side effects.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI